ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 2)

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL).

The understanding of the biology of CLL is changing how we manage CLL. Prognostic markers help to identify specific patient subgroups and provide insight disease progression in these groups. New studies in drugs, such as ibrutinib, target cell proliferation.

Year of Production:
Running Time:


Comments are closed.